https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability-en.html Drugnews｜藥時事 en 2026-07-28T00:00:00.000Z T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability.html Drugnews｜藥時事 zh-tw 2026-07-28T00:00:00.000Z T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後 https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html Drugnews｜藥時事 zh-tw 2026-07-27T00:00:00.000Z 半年千億，買的是時間 https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.html Drugnews｜藥時事 en 2026-07-27T00:00:00.000Z $130 Billion in Six Months: Big Pharma Is Buying Time